PMID- 22924642
OWN - NLM
STAT- MEDLINE
DCOM- 20130709
LR  - 20181202
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Linking)
VI  - 19
IP  - 1-2
DP  - 2013 Jan
TI  - Human embryonic stem cell-derived mesodermal progenitors display substantially 
      increased tissue formation compared to human mesenchymal stem cells under dynamic 
      culture conditions in a packed bed/column bioreactor.
PG  - 175-87
LID - 10.1089/ten.TEA.2011.0412 [doi]
AB  - Bone tissue engineering represents a promising strategy to obviate bone 
      deficiencies, allowing the ex vivo construction of bone substitutes with 
      unprecedented potential in the clinical practice. Considering that in the human 
      body cells are constantly stimulated by chemical and mechanical stimuli, the use 
      of bioreactor is emerging as an essential factor for providing the proper 
      environment for the reproducible and large-scale production of the engineered 
      substitutes. Human mesenchymal stem cells (hMSCs) are experimentally relevant 
      cells but, regardless the encouraging results reported after culture under 
      dynamic conditions in bioreactors, show important limitations for tissue 
      engineering applications, especially considering their limited proliferative 
      potential, loss of functionality following protracted expansion, and decline in 
      cellular fitness associated with aging. On the other hand, we previously 
      demonstrated that human embryonic stem cell-derived mesodermal progenitors 
      (hES-MPs) hold great potential to provide a homogenous and unlimited source of 
      cells for bone engineering applications. Based on prior scientific evidence using 
      different types of stem cells, in the present study we hypothesized that dynamic 
      culture of hES-MPs in a packed bed/column bioreactor had the potential to affect 
      proliferation, expression of genes involved in osteogenic differentiation, and 
      matrix mineralization, therefore resulting in increased bone-like tissue 
      formation. The reported findings suggest that hES-MPs constitute a suitable 
      alternative cell source to hMSCs and hold great potential for the construction of 
      bone substitutes for tissue engineering applications in clinical settings.
FAU - de Peppo, Giuseppe Maria
AU  - de Peppo GM
AD  - The New York Stem Cell Foundation, New York, New York, USA. gdepeppo@nyscf.org
FAU - Sladkova, Martina
AU  - Sladkova M
FAU - Sjovall, Peter
AU  - Sjovall P
FAU - Palmquist, Anders
AU  - Palmquist A
FAU - Oudina, Karim
AU  - Oudina K
FAU - Hyllner, Johan
AU  - Hyllner J
FAU - Thomsen, Peter
AU  - Thomsen P
FAU - Petite, Herve
AU  - Petite H
FAU - Karlsson, Camilla
AU  - Karlsson C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120928
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
SB  - IM
MH  - Batch Cell Culture Techniques/*instrumentation
MH  - *Bioreactors
MH  - Bone Development/*physiology
MH  - Cell Differentiation
MH  - Cells, Cultured
MH  - Embryonic Stem Cells/*cytology
MH  - Equipment Design
MH  - Equipment Failure Analysis
MH  - Humans
MH  - Mechanotransduction, Cellular/physiology
MH  - Mesenchymal Stem Cells
MH  - Mesoderm/*cytology
MH  - Organ Culture Techniques/*instrumentation
MH  - Osteogenesis/*physiology
EDAT- 2012/08/29 06:00
MHDA- 2013/07/10 06:00
CRDT- 2012/08/29 06:00
PHST- 2012/08/29 06:00 [entrez]
PHST- 2012/08/29 06:00 [pubmed]
PHST- 2013/07/10 06:00 [medline]
AID - 10.1089/ten.TEA.2011.0412 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2013 Jan;19(1-2):175-87. doi: 10.1089/ten.TEA.2011.0412. Epub 
      2012 Sep 28.